Onkologie. 2021:15(4):158-163 | DOI: 10.36290/xon.2021.031

Adjuvant therapy of malignant melanoma: general and practical experience

MUDr. Jindřich Kopecký, Ph.D., MUDr. Ondřej Kubeček, MUDr. Peter Priester
Klinika onkologie a radioterapie, LF a FN Hradec Králové

Over the last decade, we have witnessed remarkable progress in the treatment of malignant melanoma. Success in treating this disease is inextricably linked to understanding the molecular processes involved in its pathogenesis and the identification of critical structures controlling the immune response. Based on the results from clinical adjuvant studies, immunotherapy represented by checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) and targeted therapy (dabrafenib plus trametinib) in patients with a proven BRAF gene mutation were gradually included in the treatment algorithms.

Keywords: malignant melanoma, adjuvant therapy, targeted therapy, immunotherapy, checkpoint inhibitors.

Published: September 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopecký J, Kubeček O, Priester P. Adjuvant therapy of malignant melanoma: general and practical experience. Onkologie. 2021;15(4):158-163. doi: 10.36290/xon.2021.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36): 6199-206. Go to original source... Go to PubMed...
    2. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377(19): 1824-1835. Go to original source... Go to PubMed...
    3. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378(19): 1789-1801. Go to original source... Go to PubMed...
    4. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377(19): 1813-1823. Go to original source... Go to PubMed...
    5. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102(7): 493-501. Go to original source... Go to PubMed...
    6. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29(4): 241-52. Go to original source... Go to PubMed...
    7. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20(7): 1818-25. Go to original source... Go to PubMed...
    8. Pirard D, Heenen M, Melot C, and Vereecken P Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004; 208(1): 43-8. Go to original source... Go to PubMed...
    9. Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106(7): 1431-42. Go to original source... Go to PubMed...
    10. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366(9492): 1189-96. Go to original source... Go to PubMed...
    11. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High - and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18(12): 2444-58. Go to original source... Go to PubMed...
    12. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7-17. Go to original source... Go to PubMed...
    13. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13(11): 2776-83. Go to original source... Go to PubMed...
    14. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008; 19(6): 1195-201. Go to original source... Go to PubMed...
    15. Kleeberg UR, Suciu S, Bröcker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40(3): 390-402. Go to original source... Go to PubMed...
    16. Cameron DA, Cornbleet MC, Mackie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001; 84(9): 1146-9. Go to original source... Go to PubMed...
    17. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358(9285): 866-9. Go to original source... Go to PubMed...
    18. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22(1): 53-61. Go to original source... Go to PubMed...
    19. Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology 2020; 21(11): 1465-1477. Go to original source... Go to PubMed...
    20. Eggermont AMM, Blank CU, Mandala M, et al. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology 2020: JCO.20.02110. Go to original source... Go to PubMed...
    21. Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. New England Journal of Medicine 2020; 383(12): 1139-1148. Go to original source... Go to PubMed...
    22. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949-54. Go to original source... Go to PubMed...
    23. Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 2018; 25(8): 2105-2110. Go to original source...
    24. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine 2017; 376(23): 2211-2222. Go to original source... Go to PubMed...
    25. Leiter U, Stadler R, Mauch C, et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol 2019; 37(32): 3000-3008. Go to original source... Go to PubMed...
    26. Durham AB, Wong SL. Sentinel lymph node biopsy in melanoma: final results of MSLT-I. Future Oncol 2014; 10(7): 1121-3. Go to original source... Go to PubMed...
    27. Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes). Ann Surg Oncol 2020; 27(1): 15-21. Go to original source... Go to PubMed...
    28. Eggermont AMM, Blank CU, Mandala M, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer 2019; 116: 148-157. Go to original source... Go to PubMed...
    29. Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018; 36(35): 3441-3449. Go to original source... Go to PubMed...
    30. Bhave P, Pallan L, Long GV, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer 2021; 124(3): 574-580. Go to original source... Go to PubMed...
    31. Owen CN, Shoushtari AN, Chauhan D, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann Oncol 2020; 31(8): 1075-1082. Go to original source... Go to PubMed...
    32. Žiaran M, Dvořák P, Hoffmann P, Kopecký J. Failure of adjuvant treatment for malignant melanoma - what next? Klin Onkol 2021; 34(1): 73-77. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.